Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World

Executive Summary

Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.

Advertisement

Related Content

Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Advair: A Big Generic Opportunity And A Big Question Mark In 2017
Vaccines Unit Shines For GSK In 3Q
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Mylan Confident On Advair Generic First-Round Approval
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
GSK Reveals Big Changes As 2015 Growth Prospects Fizzle

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel